{
    "clinical_study": {
        "@rank": "38426", 
        "biospec_descr": {
            "textblock": "Blood samples to compare groups and to look for endocrine abnormalities"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a clinical study to evaluate the effect of CMPN (Chronic myeloproliferative\n      neoplasm) to the bone.\n\n      The hypothesis is that patients with CMPN have a higher fracture-rate compared to the\n      background population. We expect to find a lower BMD using conventional DXA scan (dual\n      energy x-ray absorptiometry), and a change in other parameters using HR-pQCT\n      (high-resolution peripheral quantitative computerized tomography).Biochemical bone markers\n      is measured to support the hypothesis."
        }, 
        "brief_title": "Myeloproliferative Neoplasms and Bone Structure", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Polycythemia Vera", 
            "Thrombocythemia, Essential", 
            "Primary Myelofibrosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Neoplasms", 
                "Myeloproliferative Disorders", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Thrombocythemia, Essential", 
                "Thrombocytosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a clinical study to evaluate the effect of CMPN to the bone.\n\n      Three individual cohorts are defined; a cohort consisting of 50 patients with Polycythemia\n      Vera (PV), a cohort consisting of 50 patients with Essential Thrombocythemia (ET), and a\n      cohort consisting of 25 patients with Primary Myelofibrosis (PMF).\n\n      Patients are recruited from the Department of Hematology, Odense University Hospital.\n\n      Interventions consist of:\n\n        -  Conventional DXA scan to measure Bone Mineral Density (BMD).\n\n        -  Experimental HR-pQCT to assess geometry, strength and microstructure of the bone in 3\n           dimension.\n\n        -  Blood-samples are collected and frozen for later analyses of Biochemical Bone Markers:\n           1-CTP, Ctx, ALP (alkaline phosphatase)and P1NP.\n\n      The outcome is compared to healthy control individuals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of PV (according to WHO 2008 criteria), only JAK2-pos.(Janus kinase 2)\n\n          -  Diagnosis of ET (according to WHO 2008 criteria), only JAK2-pos.\n\n          -  Diagnosis of PMF (according to WHO 2008 criteria)independent of JAK2-status.\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Bone Diseases (Mb. Pagets, Myelomatosis, MGUS (monoclonal gammopathy of undetermined\n             significance), osteogenesis imperfecta, Prim. hyperparathyroidism, osteomalacia.\n\n          -  Drugs (Prednisone>3 mth, anti-osteoporotic drugs, anti-estrogen drugs.\n\n          -  Presence of any psychologic condition or language barrier, which may interfere which\n             a complete understanding, and arise ethnical considerations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Danish patients with CMPN"
            }
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816022", 
            "org_study_id": "HFEX 11.15"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CMPN", 
            "Fracture", 
            "Osteoporosis", 
            "Biochemical Bone Markers"
        ], 
        "lastchanged_date": "March 20, 2013", 
        "location": {
            "contact": {
                "email": "mailtilsarah@yahoo.com", 
                "last_name": "Sarah Farmer, MD", 
                "phone": "+45 22324276"
            }, 
            "contact_backup": {
                "last_name": "Hanne Vestergaard, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Odense", 
                    "country": "Denmark", 
                    "state": "Region Syddanmark", 
                    "zip": "5000"
                }, 
                "name": "Faculty of Health Sciences, Institute of Clinical Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "1", 
        "official_title": "Myeloproliferative Neoplasms and Bone Structure", 
        "overall_contact": {
            "email": "mailtilsarah@yahoo.com", 
            "last_name": "Sarah Farmer, MD", 
            "phone": "+45 22324276"
        }, 
        "overall_contact_backup": {
            "email": "Hanne.Vestergaard@ouh.regionsyddanmark.dk", 
            "last_name": "Hanne Vestergaard, MD", 
            "phone": "+45 26258550"
        }, 
        "overall_official": {
            "affiliation": "Department of Hematology, Clinical Institute, University of Southern Denmark", 
            "last_name": "Sarah Farmer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: The Danish National Committee on Biomedical Research Ethics", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will undergo one DXA scan independent of time of CMPN diagnosis", 
            "measure": "Bone Mineral Density (BMD)", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816022"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Southern Denmark", 
            "investigator_full_name": "Sarah Farmer", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients will undergo one HR.pQCT indepedent of the time of the diagnosis of CMPN", 
            "measure": "Evaluation of Geometry, Strength and Micro-Structure of the bone.", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "University of Southern Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Southern Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}